Blueprint Medicines has been granted a patent for a compound (Formula II-A) and its pharmaceutically acceptable salt, which can be used for treating cancer. GlobalData’s report on Blueprint Medicines gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Blueprint Medicines Corp - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Blueprint Medicines, Cancer treatment biomarkers was a key innovation area identified from patents. Blueprint Medicines's grant share as of September 2023 was 30%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11718602B2) discloses a compound of Formula (II-A) and its various derivatives. The compound is of interest in the field of pharmaceuticals due to its potential therapeutic applications.

The compound, as described in claim 1, falls under Formula (II-A). The patent specifies that the compound can exist as a pharmaceutically acceptable salt, with m being 1, 2, 3, 4, or 5. Additionally, each R1 in the compound can independently represent halogen, CN, OH, NRaRb, C1-C4 alkyl, C1-C4 alkoxy, or —O-C3-C6 cycloalkyl. It is important to note that the alkyl, alkoxy, or cycloalkyl groups represented by R1 can be optionally substituted with 1 to 3 groups selected from deuterium, halogen, OH, NRaRb, C1-C2 alkyl, and C1-C2 alkoxy.

Claim 2 further specifies that in the compound described in claim 1, at least one R1 must be OH, C1-C4 alkoxy, or —O-C3-C6 cycloalkyl. Similar to claim 1, the alkoxy or cycloalkyl groups represented by R1 can be optionally substituted with 1 to 3 groups selected from deuterium, halogen, OH, NRaRb, C1-C2 alkyl, and C1-C2 alkoxy.

Claim 4 provides a comprehensive list of possible substitutions for each R1 in the compound described in claim 2. The substitutions include F, CN, OH, NH2, CH3, CH2CH3, CHF2, CH(OH)CH3, CH2OH, CH2NH2, CH2CH2NH2, OCH3, OCD3, OCH2CH2OH, OCH2CH(OH)CH3, OCH2C(OH)(CH3)2, OCH2CH2OCH3, OCH2CH2NH2, OCH2CH2NHCH3, OCH2CH2N(CH3)2, —O- cyclopropyl, NHCH3, or N(CH3)2.

Claim 6 introduces the concept of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound described in claim 1 or its pharmaceutically acceptable salt. This claim highlights the potential use of the compound in the development of new drugs.

Overall, this granted patent provides valuable information about a compound and its derivatives, which could have significant implications in the field of pharmaceutical research and development. The compound's diverse substituent options and potential therapeutic applications make it an interesting subject for further investigation and potential drug development.

To know more about GlobalData’s detailed insights on Blueprint Medicines, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies